[go: up one dir, main page]

KR950000150A - 입사피론 의약 제제 - Google Patents

입사피론 의약 제제 Download PDF

Info

Publication number
KR950000150A
KR950000150A KR1019940013308A KR19940013308A KR950000150A KR 950000150 A KR950000150 A KR 950000150A KR 1019940013308 A KR1019940013308 A KR 1019940013308A KR 19940013308 A KR19940013308 A KR 19940013308A KR 950000150 A KR950000150 A KR 950000150A
Authority
KR
South Korea
Prior art keywords
pharmaceutical formulation
incident
diffusion
pyrone
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019940013308A
Other languages
English (en)
Inventor
세르노 페터
피셔 볼프강
루프 롤란트
베르자벨 마르크
텐터 울리히
쉬므트 게르하르트
쉘른함머 귄터
암멘 마리아
마에가따 신지
Original Assignee
크누트 샤우에르테, 클라우스 데너
바이엘 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크누트 샤우에르테, 클라우스 데너, 바이엘 악티엔게젤샤프트 filed Critical 크누트 샤우에르테, 클라우스 데너
Publication of KR950000150A publication Critical patent/KR950000150A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 활성 화합물의 한정된 방출을 갖는 확산 제어 펠릿 또는 침식 정제로 이루어진 지속적인 작용, 고생체이용율 및 양호한 저장 안정성을 갖는 입사피론 의약 제제 및 그의 제조 방법 및 용도에 관한 것이다.

Description

입사피론 의약 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예 6의 본 발명의 서방 제제와 실시예 1의 즉시 방출 입사피론 정제의 방출 시험 결과를 비교 도시한 그래프.

Claims (10)

  1. 80%/5시간 내지 80%/13시간의 평균 방출 속도 및 방출 초기 2시간 동안 35% 미만의 입사피론이 방출되는 초기 방출 속도를 갖는 입사피론 제약 제제.
  2. 제1항에 있어서, 확산 제어 펠릿 또는 정제 형태의 입사피론 제약 제제.
  3. 제2항에 있어서, 확산 제어 펠릿이 활성 화합물 및 결합제의 혼합물로 코팅시키고, 이어서, 확산층으로 코팅시킨 중심 펠릿으로 이루어진 것이 특징인 입사피론 제약 제제.
  4. 제2항 또는 제3항에 있어서, 확산층이 통상적인 확산 래커 및 통상적인 가소제로 이루어진 것이 특징인 확산 제어 펠릿 형태의 입사피론 제약 제제.
  5. 제2항 내지 제4항중 어느 한 항에 있어서, 히드록시프로필메틸셀룰로오스를 결합제로서 사용하고, Aquacoat를 확산 래커로서 사용하고, 트리아세틴을 가소제로 사용하는 것이 특징인 확산 제어 펠릿 형태의 입사피론 제약 제제.
  6. 활성 화합물을 필요에 따라 첨가제와 함께 물에 현탁시키거나 용해시키고, 결합제의 용액으로 농후화시키고, 이 현탁액을 중심 펠릿에 도포시키고, 이 코팅된 펠릿을 확산 래커와 가소제의 혼합물로 코팅시키는 것이 특징인 제2항 내지 제5항 기재의 확산 제어 펠릿형 입사피론 제약 제제의 제조 방법.
  7. 제2항에 있어서, 활성 화합물 및 통상적인 정제 제조용 보조제 이외에 수용성, 히드로겔 형성 중합체를 함유하는 정제 형태의 입사피론 제약 제제.
  8. 제7항에 있어서, 활성 화합물 이외에 150mPa·s 이상의 점도를 갖는 히드록시프로필셀룰로오스 50mg 이상을 함유하는 것이 특징인 정제 형태의 입사피론 제약 제제.
  9. 제1항 내지 제7항중 어느 한 항에 있어서, 추가로 생리학적으로 허용되는 산을 함유하는 것을 특징인 입사피론 제약 제제.
  10. 불안증 및 우울증 치료를 위한 제1항 내지 9항 기재의 입사피론 제제의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940013308A 1993-06-15 1994-06-14 입사피론 의약 제제 Withdrawn KR950000150A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4319760.4 1993-06-15
DE4319760A DE4319760A1 (de) 1993-06-15 1993-06-15 Ipsapiron Arzneimittelzubereitung

Publications (1)

Publication Number Publication Date
KR950000150A true KR950000150A (ko) 1995-01-03

Family

ID=6490360

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940013308A Withdrawn KR950000150A (ko) 1993-06-15 1994-06-14 입사피론 의약 제제

Country Status (16)

Country Link
EP (1) EP0629402A1 (ko)
JP (1) JPH06345649A (ko)
KR (1) KR950000150A (ko)
CN (1) CN1099263A (ko)
AU (1) AU6345794A (ko)
CA (1) CA2125620A1 (ko)
CZ (1) CZ146494A3 (ko)
DE (1) DE4319760A1 (ko)
FI (1) FI942803L (ko)
HU (1) HUT70759A (ko)
IL (1) IL109993A0 (ko)
NO (1) NO942228L (ko)
NZ (1) NZ260732A (ko)
PL (1) PL303822A1 (ko)
SK (1) SK72494A3 (ko)
ZA (1) ZA944187B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
HUP0104778A3 (en) * 1998-12-24 2004-05-28 Janssen Pharmaceutica Nv Controlled release galantamine composition
WO2004103338A1 (en) * 2003-05-19 2004-12-02 Bioprogress Plc Adhesives and film modifying compositions
EP4062913B1 (en) * 2020-09-02 2024-05-08 Beijing Biostar Pharmaceuticals Co., Ltd. Solid oral formulation of utidelone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE79029T1 (de) * 1989-02-11 1992-08-15 Bayer Ag Arzneimittel mit kontrollierter wirkstoffabgabe.
DD297767A5 (de) * 1990-03-06 1992-01-23 Bayer Aktiengesellschaft,De Arzneimittel mit kontrollierter wirkstoffabgabe
JPH04360826A (ja) * 1991-06-07 1992-12-14 Bayer Yakuhin Kk 放出制御製剤

Also Published As

Publication number Publication date
IL109993A0 (en) 1994-10-07
CN1099263A (zh) 1995-03-01
AU6345794A (en) 1994-12-22
SK72494A3 (en) 1995-04-12
CA2125620A1 (en) 1994-12-16
CZ146494A3 (en) 1995-01-18
JPH06345649A (ja) 1994-12-20
NO942228D0 (no) 1994-06-14
ZA944187B (en) 1995-02-08
FI942803A7 (fi) 1994-12-16
NO942228L (no) 1994-12-16
FI942803A0 (fi) 1994-06-13
EP0629402A1 (de) 1994-12-21
NZ260732A (en) 1996-02-27
HUT70759A (en) 1995-10-30
PL303822A1 (en) 1995-01-09
FI942803L (fi) 1994-12-16
HU9401771D0 (en) 1994-09-28
DE4319760A1 (de) 1994-12-22

Similar Documents

Publication Publication Date Title
US8747898B2 (en) Controlled release oral dosage form
ES2606463T3 (es) Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada
AU757915B2 (en) Controlled release bupropion formulation
EP0250267A2 (en) Controlled absorption pharmaceutical composition
JPH0643312B2 (ja) 薬学的調合剤
CA1319616C (en) Long-acting diclofenac sodium preparation
CA2686094A1 (en) Manufacturing method of a semiconductor element
PL191692B1 (pl) Sposób wytwarzania doustnych, stałych produktów farmaceutycznych z regulowanym wydzielaniem substancji czynnej
JPS6323814A (ja) 経口投与形体の徐放性医薬組成物
US10213389B2 (en) Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
MX2010011409A (es) Forma oral solida con perfil de liberacion dual que contiene particulas multiples.
JP2863528B2 (ja) ジルチアゼムを含有する徐放性製剤の製造方法
SE8300577L (sv) Overdrag som tillforsekrar reglerad avgivning av akriva bestandsdelar fran biologiskt aktiva blandningar, i synnerhet farmaceutiska beredningar, jemte sett att framstella biologiskt aktiva blandningar med reglerad ....
EP0211991A1 (en) Substained release tablets and method for preparation thereof
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
KR950000150A (ko) 입사피론 의약 제제
DE60319983T2 (de) Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan
CA2433915C (en) Improved controlled release oral dosage form
DE112006001548T5 (de) Ticlopidin-Zusammensetzungen mit modifizierter Freisetzung
JP2024136895A (ja) 徐放性コーティング組成物
JP2947841B2 (ja) 徐放性固形製剤
Ayesha Farhana et al. Sustained release of verapamil hydrochloride from sodium alginate microcapsules
JP2005510449A (ja) 改良型制御放出経口剤形
CN119866214A (zh) 一种缓控释渗透药物组合物及其制备方法
CN115607544A (zh) 沙库巴曲缬沙坦钠缓释组合物、其制备方法及应用

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19940614

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid